ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
Akcea Therapeutics Inc

Akcea Therapeutics Inc (AKCA)

18,17
0,00
(0,00%)
Fermé 05 Décembre 10:00PM
0,00
0,00
(0,00%)
Après les heures de négociation: -

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

Dernier
18,17
Prix Achat
18,08
Prix Vente
19,00
Volume échangé
-
0,00 Fourchette du Jour 0,00
0,00 Plage de 52 semaines 0,00
Clôture Veille
18,17
Ouverture
-
Dernière Transaction
Dernière heure de transaction
Volume moyen (3 m)
-
Volume financier
-
VWAP
-

AKCA Dernières nouvelles

Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product

Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product PR Newswire BOSTON and CARLSBAD, Calif., Oct. 30, 2020 BOSTON and CARLSBAD, Calif., Oct...

Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics

Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics Transaction creates a stronger, more efficient company PR Newswire CARLSBAD, Calif., Oct. 12, 2020 CARLSBAD, Calif., Oct. 12...

WAYLIVRA▼® (volanesorsen), the First & Only Therapy for FCS, an Ultra-Rare & Life-Threatening Condition, to Be Available o...

National Institute for Health and Care Excellence (NICE) issues a positive recommendation for volanesorsen to treat adults with Familial Chylomicronaemia Syndrome (FCS) Akcea Therapeutics UK...

Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics

Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics - Ionis to acquire remaining 24% of common stock of Akcea it does not already own for $18.15 per share in cash - Transaction...

Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at ESC Congress 2020

Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at ESC Congress 2020 Results from Phase 2 study demonstrate patients receiving vupanorsen experienced significant...

Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx) Presented at ESC Congress 2020

Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx) Presented at ESC Congress 2020 Results in late-breaking presentation show patients with hypertriglyceridemia experienced dose-dependent...

Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (Rx) ) at ESC Congress 2020

Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (Rx) ) at ESC Congress 2020 Late-breaking presentation to focus on efficacy and safety data of vupanorsen in...

Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020

Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020 Data presentation will highlight efficacy, safety and tolerability of...

Akcea Announces New Pricing and Reimbursement of WAYLIVRA® (volanesorsen) in Germany

Akcea Announces New Pricing and Reimbursement of WAYLIVRA® (volanesorsen) in Germany WAYLIVRA is the only treatment option for patients with familial chylomicronemia syndrome, or FCS, in...

Akcea Reports Financial Results and Highlights for Second Quarter 2020

Akcea Reports Financial Results and Highlights for Second Quarter 2020 Global Net Product Revenues of $16 Million, an Increase of 66% Year-Over-Year Achieved Pricing and Reimbursement Across Key...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
CYCNCyclerion Therapeutics Inc
US$ 6,10
(278,88%)
141,56M
BLUEbluebird bio Inc
US$ 0,7396
(106,30%)
79,23M
SMXSMX Security Matters Public Company
US$ 0,381378
(95,78%)
826,63M
SRMSRM Entertainment Inc
US$ 1,15
(82,51%)
143,64M
CNEYCN Energy Group Inc
US$ 0,5349
(69,49%)
164,13M
RLMDRelmada Therapeutics Inc
US$ 0,6408
(-76,87%)
17,99M
MIGIMawson Infrastructure Group Inc
US$ 0,6885
(-63,95%)
23,35M
MONDMondee Holdings Inc
US$ 0,192
(-34,94%)
4,1M
ORISOriental Rise Holdings Ltd
US$ 8,02
(-32,89%)
675,31k
HTLMHomesToLife Ltd
US$ 3,10
(-27,57%)
162,95k
SMXSMX Security Matters Public Company
US$ 0,381378
(95,78%)
826,63M
SVMHSRIVARU Holding Ltd
US$ 0,023499
(6,81%)
475,49M
HTOOFusion Fuel Green PLC
US$ 0,5199
(63,49%)
279,78M
NVDANVIDIA Corporation
US$ 145,14
(3,48%)
231,22M
CNEYCN Energy Group Inc
US$ 0,5349
(69,49%)
164,13M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock